Most stomach cancer symptoms look ordinary at first: indigestion after meals, mild nausea, feeling full sooner than usual, a dull ache below the ribs. Those complaints are far more often caused by reflux, an ulcer, or gastritis, which is why gastric cancer is usually found late in the United States. One part of this story deserves more attention than it gets: a common stomach bacterium called Helicobacter pylori is the largest preventable cause of gastric cancer, it can be found with a breath or stool test, and treating it lowers future risk. In this article you will learn which symptoms are worth acting on, how H. pylori fits in, how the diagnosis is made, and what lab results can and cannot say about the stomach.
What stomach cancer is and why it is usually found late
Stomach cancer, also called gastric cancer, begins when cells in the stomach lining grow abnormally and form a tumor. About nine out of ten cases are adenocarcinomas, arising from the mucus-producing gland cells of the wall. Tumors near the junction with the esophagus are more often linked with long-standing reflux and obesity, while tumors lower down are linked with chronic infection. A separate pattern, diffuse gastric cancer, spreads through the wall without forming an obvious lump, which makes it harder to see and more likely to affect younger adults.
Why late diagnosis is the norm in the United States
The stomach is a stretchy organ, so a small tumor can sit in the lining for a long time without blocking anything or causing pain. By the time symptoms are impossible to ignore, it has often grown through the wall or reached nearby lymph nodes. American gastroenterology groups say this plainly: only a small share of cases here are caught at the early, curable stage.
Stomach cancer symptoms: the vague ones and the red flags
Understanding stomach cancer symptoms means separating two groups: one common, non-specific, and almost always benign in origin; the other uncommon, more specific, and worth a medical visit even when you otherwise feel well.
Early symptoms that overlap with everyday conditions
Persistent indigestion, burning discomfort, bloating, early fullness during meals, mild nausea, and loss of appetite are the usual early complaints, and every one is shared with reflux disease, peptic ulcers, and inflammation of the stomach lining. Anyone weighing that overlap will find the picture clearer after reading a full explanation of gastritis symptoms and causes. The point is not that indigestion is dangerous — it usually is not — but that indigestion which is new, lasts several weeks, or differs from your usual pattern deserves a proper look rather than an indefinite run of antacids.
Red flags that change the picture
A smaller set carries real weight because it suggests bleeding, obstruction, or systemic effects rather than simple irritation:
- Difficulty swallowing, or food sticking on the way down
- Vomiting blood, or vomit that looks like coffee grounds
- Black, tarry stools, meaning digested blood from the upper gut
- Unexplained weight loss without dieting
- Persistent vomiting, especially after meals
- New indigestion beginning after roughly age 60
- A stomach complaint together with new anemia on a blood test
None of these proves cancer; ulcers and severe reflux cause them too. What they share is that each justifies an examination of the stomach.
How the same symptom reads differently in context
| Symptom | Usual explanation | What makes it worth a closer look |
|---|---|---|
| Indigestion or burning | Reflux, gastritis, ulcer | New after age 60, lasting weeks, or not responding to treatment |
| Feeling full quickly | Functional dyspepsia, slow emptying | Meal sizes shrinking steadily, with weight loss |
| Dark stools | Iron tablets, bismuth, certain foods | Black and tarry with no supplement to explain it |
H. pylori: the largest cause you can actually do something about
Helicobacter pylori is a spiral-shaped bacterium that settles in the stomach lining, usually in childhood, and can persist for life without announcing itself. It affects a substantial minority of American adults. Most carriers never develop cancer, but among the causes of gastric cancer that can be identified and removed, this infection is by far the biggest.
How a bacterium becomes a cancer risk
The sequence unfolds over decades. Chronic infection produces long-standing inflammation; over years the acid-producing glands thin out, a state called atrophic gastritis; the lining may then be replaced by cells resembling those of the intestine, called intestinal metaplasia. In a minority of people those cells accumulate further abnormalities and turn into cancer. Most never reach the end of the chain — which is why interrupting it early is worthwhile.
Who should be tested, and how
Testing needs no procedure. A urea breath test detects the enzyme the bacterium uses to survive in acid. A stool antigen test detects fragments of the organism directly, and readers can review a plain-language explanation of the H. pylori stool antigen test beforehand. Blood antibody tests are less useful because they stay positive long after successful treatment. American guidance supports testing people with ulcers, unexplained upper-gut symptoms, precancerous stomach changes, a first-degree relative with gastric cancer, or a household member who tested positive. Both tests need acid-suppressing medication stopped about two weeks beforehand, or a real infection can be missed.
What treatment involves, and why confirmation matters
Eradication means two or more antibiotics with an acid-reducing drug, typically for ten to fourteen days. Resistance has made older regimens less reliable, so the combination is chosen from local patterns and antibiotics you have taken before. The step people most often skip is the confirmation test, at least four weeks after treatment ends — and the benefit depends on the infection actually being gone.
Precancerous changes, other risk factors and inherited risk
Atrophic gastritis and intestinal metaplasia
These two findings often appear on a pathology report after an endoscopy done for another reason, and they alarm people who read them without context. They are not cancer. They describe a lining inflamed for a long time and changed in a way that raises risk modestly. Whether repeat endoscopy is advised depends on how extensive the changes are and on family history. For most people the changes are limited and no surveillance is recommended; for extensive or severe changes, a repeat examination roughly every three years is usual.
Risk factors beyond infection
- Smoking, the second most important modifiable factor
- Diets heavy in salt-preserved, smoked, or pickled foods and light in fruits and vegetables
- Heavy alcohol use, and obesity for tumors near the esophagus
- Previous stomach surgery, or certain stomach polyps
- Autoimmune gastritis, where the immune system attacks acid-producing cells
- Gastric cancer in a parent, sibling, or child
- Age, since most cases occur after 60, and male sex
Hereditary diffuse gastric cancer and the CDH1 gene
A small share of cases run in families through an inherited change in a gene called CDH1, which normally helps cells stick together. Carriers have a high lifetime risk of the diffuse type, and women in these families also face raised breast cancer risk. Because diffuse tumors spread within the wall rather than forming a visible lump, endoscopy is an imperfect safety net, and preventive removal of the stomach is discussed in specialized centers. A genetics referral is warranted when gastric cancer struck a close relative young, when two or more relatives are affected, or when diffuse gastric cancer and lobular breast cancer appear in one family. Lynch syndrome raises stomach risk alongside the risk of colorectal cancer.
How stomach cancer is diagnosed
Endoscopy with biopsy is the test that answers the question
Upper endoscopy, or gastroscopy, is the definitive investigation. A thin flexible camera passes through the mouth into the stomach under sedation, letting the doctor inspect the lining and take tissue samples. Only a pathologist examining that tissue can confirm or rule out cancer. Nothing else — not a blood test, not an ultrasound, not a symptom checklist — substitutes for it. Modern practice adds image-enhanced techniques that make flat lesions easier to see, plus a biopsy protocol sampling both the upper and lower stomach.
If cancer is confirmed, staging follows: a CT scan, often endoscopic ultrasound to judge how deeply the tumor invades the wall, and sometimes a laparoscopy.
Why the United States does not screen the whole population
Japan and South Korea invite adults to regular stomach screening from around age 40 to 50, and both diagnose a large share of cases at an early, curable stage. The United States does not, and the reason is arithmetic rather than neglect: stomach cancer is several times more common in Japan and Korea, so screening there finds enough disease to justify the cost, the endoscopy capacity, and the small risks of the procedure. At American rates, a national program would examine an enormous number of healthy stomachs per cancer found. Expert groups here advise a targeted approach instead, for first-generation immigrants from high-incidence regions, people with a first-degree relative who had gastric cancer, and people with known precancerous changes.
What blood and stool tests can and cannot tell you
No blood test screens for or diagnoses stomach cancer
This is one of the most common misunderstandings about the disease. No blood test screens for gastric cancer, and none can diagnose it. A normal panel does not rule it out, and an abnormal result does not establish it. Diagnosis runs through endoscopy and biopsy.
The lab clues that sometimes appear first
Laboratory results still matter, because a tumor that bleeds slowly can produce iron-deficiency anemia long before it causes pain. Unexplained iron deficiency in an adult, particularly a man or a postmenopausal woman, is a recognized reason to look inside the upper gut. The relevant tests include a complete blood count, which may show small pale red cells, and a hemoglobin measurement that has drifted down. Iron stores are judged from a ferritin level and a serum iron measurement, and many patients then want the wider picture of anemia and its causes. Because atrophic gastritis reduces absorption, doctors may also request a vitamin B12 level. Stool testing can detect invisible blood, and many people meet this idea through a fecal occult blood test result — a test designed for colorectal screening, not for the stomach.
Tumor markers: a monitoring role only
Two markers are sometimes measured in people already diagnosed, to follow treatment and watch for recurrence rather than to detect disease. A carcinoembryonic antigen result can rise with several cancers and also with smoking, liver disease, and inflammation. A CA 19-9 measurement behaves similarly and is normal in many people with confirmed cancer. Neither is a screening test, and a normal value should never dismiss red-flag symptoms.
Treatment today
Endoscopic resection and surgery
Very early tumors confined to the surface layer can sometimes be removed through the endoscope itself, using endoscopic submucosal dissection. More advanced tumors need surgery to remove part or all of the stomach with nearby lymph nodes. Afterwards meals become smaller and more frequent, and long-term monitoring of iron, vitamin B12, and calcium is standard because the reshaped gut absorbs them less efficiently.
Chemotherapy before and after surgery
For tumors that have grown into the wall or reached lymph nodes, treatment is rarely surgery alone. Perioperative chemotherapy — several cycles before the operation and several after — shrinks the tumor, treats microscopic spread, and improves the chance of complete removal. Radiation is added in selected cases.
HER2 and PD-L1 testing guide modern drug choices
Biopsy tissue is now routinely tested for markers that determine which drugs are likely to work. Roughly one in five gastric tumors overproduces a protein called HER2, and these respond to trastuzumab, an antibody that targets it. Tumors are also tested for PD-L1, which helps cancer cells hide from the immune system; when enough is present, immunotherapy such as pembrolizumab or nivolumab is added to chemotherapy. A third test looks for mismatch repair deficiency, which predicts a strong immunotherapy response. The National Cancer Institute treatment summary for stomach cancer describes these options for patients and families.
When to see a doctor
Most stomach cancer symptoms never turn out to be cancer, but a few patterns deserve a professional opinion. Book an appointment without waiting if you have trouble swallowing, are vomiting blood, or are passing black tarry stools. Arrange a visit within a few weeks for indigestion lasting more than three or four weeks, indigestion starting for the first time after about age 60, unexplained weight loss, repeated vomiting, or a new anemia result. Ask specifically about H. pylori testing if you have ongoing upper-gut symptoms, a close relative with gastric cancer, or a household member who tested positive. Symptoms that are mild, longstanding, and unchanged are reassuring rather than alarming — but still worth one conversation.
Latest scientific advances
Research over the last three years strengthens one message: treating H. pylori is a genuine cancer-prevention measure.
Clearing the infection lowers the chance of ever developing stomach cancer
A 2025 review in the journal Gastroenterology pooled eleven randomized trials — studies where participants are assigned by chance to treatment or no treatment — with thirteen observational studies. Treating the infection in otherwise healthy carriers cut the number who later developed gastric cancer by roughly a third, and reduced deaths from it. What this means for you: if a test shows the infection, completing the full course is one of the few concrete steps available for lowering your risk.
Some precancerous changes can improve after treatment
A 2023 analysis of fifteen studies found that eradication slowed the progression of precancerous changes and, in a meaningful share of people, let atrophy and early intestinal metaplasia partly reverse. The effect was clearest for milder changes; established dysplasia did not improve. What this means for you: a report mentioning atrophic gastritis or intestinal metaplasia is not a one-way street, and clearing the infection is worth doing at that stage rather than later.
Confirming that treatment worked is part of the benefit
A 2024 analysis of seven studies covering close to nine thousand infected people compared those whose treatment succeeded with those whose treatment failed or who became reinfected. The group that did not end up infection-free carried a clearly higher risk, and the gap widened over ten years. What this means for you: the confirmation test is not optional — it tells you whether you gained the protection.
American guidance has moved toward targeted, risk-based screening
In 2024 and 2025 two major United States gastroenterology bodies published new guidance on precancerous stomach conditions. Both concluded there is not yet enough evidence to screen entire American populations by endoscopy, but both recommended testing and treating H. pylori in anyone with precancerous changes, plus endoscopic follow-up roughly every three years when those changes are extensive or severe. What this means for you: whether screening makes sense is an individual conversation, not a national rule.
These findings come from systematic reviews and expert guidelines rather than single studies, which makes them relatively reliable. They describe averages across large groups, and none predicts what will happen to one person.
Glossary
| Term | Definition |
|---|---|
| Adenocarcinoma | A cancer that starts in the gland cells lining an organ. About nine in ten stomach cancers are of this type. |
| Atrophic gastritis | A stomach lining that has thinned after years of inflammation, with fewer acid-producing glands than normal. |
| Intestinal metaplasia | A change in which stomach lining cells are replaced by cells that look like those of the intestine. It is a precancerous state, not cancer. |
| Dysplasia | Cells that look clearly abnormal under the microscope but have not yet become invasive cancer. |
| Eradication therapy | A ten to fourteen day course of antibiotics plus an acid-reducing drug used to clear a Helicobacter pylori infection. |
| Endoscopy | An examination in which a thin flexible camera is passed into the stomach so the lining can be seen and sampled. |
| HER2 | A protein that some tumors overproduce. Tumors that carry it can be treated with drugs designed to target it. |
| PD-L1 | A protein that helps cancer cells avoid the immune system. Its presence guides the use of immunotherapy. |
| CDH1 | A gene that helps cells stick together. Inherited faults in it cause hereditary diffuse gastric cancer. |
| Perioperative chemotherapy | Chemotherapy given both before and after surgery to shrink the tumor and treat microscopic spread. |
Frequently asked questions
What are the first warning signs of stomach cancer?
There is rarely a single dramatic sign. The earliest stomach cancer symptoms are usually persistent indigestion, discomfort in the upper abdomen, feeling full after small meals, mild nausea, and a gradual loss of appetite. Because these overlap almost completely with reflux, ulcers, and gastritis, they are not useful on their own. What raises concern is the pattern: symptoms that are new, that persist for several weeks, that are getting worse rather than better, or that arrive alongside weight loss, difficulty swallowing, vomiting, or an unexplained drop in blood counts. If you notice that combination, a medical assessment is the right next step.
Can a blood test detect stomach cancer?
No. No blood test screens for or diagnoses gastric cancer. Blood work can reveal indirect clues — most often iron-deficiency anemia from slow bleeding — that give a doctor a reason to look inside the stomach with an endoscope. Tumor markers such as carcinoembryonic antigen and CA 19-9 are used to monitor people already diagnosed, not to find disease in healthy people; they are frequently normal in confirmed cancer and frequently raised for harmless reasons. Only endoscopy with a biopsy can confirm or exclude the diagnosis.
Does having H. pylori mean I will get stomach cancer?
No. The infection is common and the great majority of people who carry it never develop gastric cancer. It raises risk rather than causing the disease directly, and the process takes decades when it happens at all. The useful conclusion is not to worry about the infection but to test for it if you have symptoms or risk factors, to complete treatment if it is found, and to confirm afterwards that it has cleared.
Is stomach cancer hereditary?
Most cases are not inherited. Around one in ten people diagnosed has a family history, and only a small fraction of those are caused by a specific inherited gene fault such as CDH1. Having a parent, sibling, or child with gastric cancer does raise your own risk somewhat, which is a good reason to be tested for H. pylori and to mention the history to your doctor. Genetic counseling is generally offered when cancer appeared at a young age, when several relatives are affected, or when diffuse gastric cancer and lobular breast cancer occur in the same family.
How is stomach cancer different from gastritis or an ulcer?
Gastritis is inflammation of the stomach lining and an ulcer is a break in it; both are common, both are usually treatable, and both often share a cause with gastric cancer in the form of H. pylori. They are not cancer and do not usually become cancer. The symptoms genuinely overlap, which is why doctors rely on endoscopy rather than symptom patterns when red flags are present or when treatment does not work as expected.
Why does the United States not screen everyone for stomach cancer?
Because stomach cancer is far less common here than in Japan or South Korea, where national programs exist. Screening works best when a disease is frequent enough that examining large numbers of healthy people finds enough cancers to justify the cost and the small risks of the procedure. At United States rates, that balance does not hold nationally. American expert groups instead recommend targeted assessment for higher-risk groups, including people from regions where the disease is common, people with a close relative who had it, and people with known precancerous changes in the stomach lining.
Sources
- MedlinePlus, National Library of Medicine — Stomach Cancer — NIH, 2025 — https://medlineplus.gov/stomachcancer.html
- Mayo Clinic — Stomach cancer: symptoms and causes — Mayo Foundation for Medical Education and Research, 2025 — https://www.mayoclinic.org/diseases-conditions/stomach-cancer/symptoms-causes/syc-20352438
- National Cancer Institute — Stomach (Gastric) Cancer Treatment (PDQ) Patient Version — NIH, 2025 — https://www.cancer.gov/types/stomach/patient/stomach-treatment-pdq
- Ford AC, Yuan Y, Park JY, Forman D, Moayyedi P — Eradication Therapy to Prevent Gastric Cancer in Helicobacter pylori-Positive Individuals: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies — Gastroenterology, 2025 — https://doi.org/10.1053/j.gastro.2024.12.033
- Zhu F, Zhang X, Li P, Zhu Y — Effect of Helicobacter pylori eradication on gastric precancerous lesions: a systematic review and meta-analysis — Helicobacter, 2023 — https://doi.org/10.1111/hel.13013
- Luo X, Qi S, Chen M, Gan T, Lv X, Yang J, Deng K — Maintaining H. pylori Negativity After Eradication Can Consolidate Its Benefit in Gastric Cancer Prevention: A Meta-Analysis — Clinical and Translational Gastroenterology, 2024 — https://doi.org/10.14309/ctg.0000000000000742
- Shah SC, Wang AY, Wallace MB, Hwang JH — AGA Clinical Practice Update on Screening and Surveillance in Individuals at Increased Risk for Gastric Cancer in the United States: Expert Review — Gastroenterology, 2025 — https://doi.org/10.1053/j.gastro.2024.11.001
- Morgan DR, Corral JE, Li D, Montgomery EA, Riquelme A, Kim JJ, Sauer B, Shah SC — ACG Clinical Guideline: Diagnosis and Management of Gastric Premalignant Conditions — The American Journal of Gastroenterology, 2025 — https://doi.org/10.14309/ajg.0000000000003350
Further reading
- Readers comparing upper digestive cancers often consult a guide to pancreatic cancer symptoms and treatment.
- People reviewing abdominal warning signs also read an overview of liver cancer symptoms and causes.
- Anyone who has noticed a change in their stools can review an explanation of visible blood in stool results.
- Many people preparing for digestive testing use an online stool test analyzer.
- Anyone facing an unfamiliar report will appreciate a practical guide to reference ranges and flagged results.
Understand your lab results with BloodSense
Stomach cancer symptoms overlap so heavily with everyday digestive complaints that the lab work ordered to sort them out can be just as confusing. BloodSense reads your results in plain language and shows how findings such as a low blood count, low iron stores, a vitamin B12 level, or a positive H. pylori stool test fit together with what you are experiencing. It helps you understand what your numbers mean and what to ask about, so your next conversation with your doctor is a better one. BloodSense does not diagnose and does not replace medical care.
